Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
I too here first invested many years ago, when, can you believe it, Dr Willy was in charge. ( No joke)
I sold out probably 5 years ago but have always watched this slowly develop, and am now back in with 100K of stock.
I like round numbers, and am happy with a slow gentle rise ( the stock lol) 3% a week ( £3K) all in my ISA, I see many many months of an ever increasing share price, especially from these low levels.
The market will catch on eventually!!
Yes, good post Donnysmind, well researched.
I note the Tap Global website has been updated to show in excess of 300,000 users now.
I’ll be interested to see how long it takes for the 500K user threshold to be made.
Very happy to keep adding on the quiet.
Such a status is given to a drug when annual Global Sales achieve $1Billion.
So, following info from the recent Trading update, if 50% of men over 40 have ED issues & 25% are new diagnoses of those under 40 then it’s a monstrous market.
A huge proportion will not seek help but will buy a product ‘in cognito’ OTC.
There are no cultural barriers here, Eroxon, now launched and gathering market share rapidly, will be distributed Globally and sales will grow exponentially.
When will the first offer be made for the Company, and at what price?
150K yesterday & 129K today.
Seems that the MM’s pull it down on teeny sells but don’t lift it on reasonable buys, they are waiting for Volume to arrive, which will come with US launch news.
Then watch the re-rate.
The Fact is, Futura have launched a product ( after spending many millions and years receiving regulatory approvals) and within a very short period it has already taken 20% of its target market.
This isn’t just outstanding, it’s phenomenal.
To gain that sort of traction with an unknown product in a new market is simply, amazing.
Ask any advertising expert, it takes years & millions in campaigns to educate the general public with a new product.
Eroxon is a product that is going to take a significant slice of the Global ED market.
Imagine the trading Volumes once Eroxon US launch is announced.
Best to accumulate target holdings prior to that imo.
Is Underway.
The revenues are just going to grow & grow.
The ED market is circa $4.72Billion, and growing.
If Eroxon take 20% annual revenues could be circa $900M in time.
It’s going to be difficult to keep this down for much longer.
Things are looking Up.
If that’s an effort to Fresno the stock it’s a bit silly.
The NHS PAY Futura PLC for the ‘goods’ and it’s free to the patient.
Good post Flava.
https://www.nasdaq.com/market-activity/stocks/rnlx#google_vignette
Look at the Volume for Renalytix on the NASDAQ, not just the closing price yesterday. ( Divide by 2).
Https://www.nasdaq.com/market-activity/stocks/rnlx#google_vignette
An Hour Well Spent.
https://m.youtube.com/watch?v=MfRToHti858&pp=ygUVcmFuZHkgYmFyb24gcmVuYWx5dGl4
This is looking good for a top up, who’s going to go first?
Hilarious that the MM’s put a 35% rise on open, having already gapped it up !
I’ve plopped 9K at 45p, 15p less than they’re paying in the US. Happy days.
Watch Randy Baron on YouTube discuss Renalytix, 2 years but very very informative.